Actively Recruiting

Phase 2
Age: 12Years - 17Years
All Genders
NCT06732895

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

Led by Ascendis Pharma A/S · Updated on 2026-04-21

24

Participants Needed

5

Research Sites

142 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.

CONDITIONS

Official Title

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

Who Can Participate

Age: 12Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written, signed informed consent and/or assent as required by ethical committees
  • Male or female aged 12 (inclusive) to 18 years at randomization
  • Clinical diagnosis of Achondroplasia with documented genetic confirmation
  • Parent(s)/legal guardian(s) able to administer weekly subcutaneous injections and follow protocol
  • At least one standing height measurement from medical records taken 6 to 15 months before screening
Not Eligible

You will not qualify if you...

  • Participation in any interventional clinical trial with investigational medicinal product (IMP) within 3 months prior to screening
  • Decreased growth velocity (less than 1.5 cm/year over at least 6 months) or evidence of growth plate closure
  • Known or suspected hypersensitivity to the investigational medicinal product or related substances
  • Presence of other growth disorders or medical conditions causing short stature such as SADDAN, hypochondroplasia, growth hormone deficiency, Turner syndrome, pseudo-Achondroplasia, inflammatory bowel disease, celiac disease, thyroid disorders, or diabetes mellitus
  • Severe FGFR3 gene mutations or severe Achondroplasia with developmental delay and acanthosis nigricans
  • Prior treatment with medications or surgeries affecting growth or body proportions
  • Requirement or expected need for chronic or repeated systemic corticosteroid treatment during the trial
  • History of injury or disease affecting growth plates other than Achondroplasia
  • Bone-related surgeries affecting growth potential, except certain reconstructive surgeries with full recovery
  • Clinically significant conditions at screening that may affect trial participation or safety including severe untreated sleep apnea, certain fractures, or other investigator-assessed fitness issues
  • Abnormal cardiac function or conduction disorders including repaired or unrepaired coarctation and complex congenital heart diseases
  • QTcF interval equal to or greater than 450 msec at screening
  • Conditions impacting hemodynamic stability such as autonomic dysfunction or orthostatic intolerance
  • Chronic anemia (except resolved iron deficiency anemia), chronic renal insufficiency, or chronic/recurrent illnesses affecting hydration or nutrition
  • History or presence of malignant disease
  • Serum vitamin D levels below 30 nmol/L at screening (unless supplemented according to local standards)
  • Any condition or situation that may prevent trial completion, confound results, or increase risk
  • Sexually active participants and partners not using highly effective contraception during and 90 days after the trial
  • Female participants who are pregnant, lactating, or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Ascendis Investigational Site

Montreal, Canada, H3T 1C5

Actively Recruiting

2

Ascendis Investigational Site

Copenhagen, Denmark, 2100

Actively Recruiting

3

Ascendis Investigational Site

Paris, France, 75743

Actively Recruiting

4

Ascendis Investigational Site

Dublin, Ireland, D01 YC76

Actively Recruiting

5

Ascendis Investigational Site

Norwich, United Kingdom, NR4 7UY

Actively Recruiting

Loading map...

Research Team

A

Ascendis Registry Inquiries

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here